V. Brichard

发表

Predictive gene signature in MAGE-A3 antigen-specific cancer immunotherapy.

Bart Spiessens, Benjamin Dizier, Stefan Suciu, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Biological and clinical developments in melanoma vaccines

P. Coulie, N. van Baren, V. Brichard, 2001, Expert opinion on biological therapy.

Genes coding for tumor antigens recognized by human cytolytic T lymphocytes.

P. Coulie, F. Brasseur, T. Boon, 1993, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

Isolation of tyrosinase-specific CD8+ and CD4+ T cell clones from the peripheral blood of melanoma patients following in vitro stimulation with recombinant vaccinia virus.

J. Thompson, S. Riddell, P. Greenberg, 1996, Journal of immunology.

Safety and Immunogenicity of the PRAME Cancer Immunotherapeutic in Patients with Resected Non–Small Cell Lung Cancer: A Phase I Dose Escalation Study

T. De Pas, J. Pujol, M. Debois, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Hypoleptinemia in patients with anorexia nervosa: loss of circadian rhythm and unresponsiveness to short-term refeeding.

J. Balligand, S. Brichard, J. Desager, 1998, European journal of endocrinology.

Immune Responses to a Class II Helper Peptide Epitope in Patients with Stage III/IV Resected Melanoma

J. Weber, V. Brichard, T. Kuus-Reichel, 2004, Clinical Cancer Research.

Expression of tumor-associated antigens in breast cancer subtypes

G. Viale, C. Criscitiello, G. Curigliano, 2019, Breast.

Safety and Immunogenicity of MAGE-A3 Cancer Immunotherapeutic with or without Adjuvant Chemotherapy in Patients with Resected Stage IB to III MAGE-A3-Positive Non–Small-Cell Lung Cancer

G. Fasola, D. Atanackovic, J. Vansteenkiste, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

1173OMAGRIT, A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED PHASE III STUDY TO ASSESS THE EFFICACY OF THE RECMAGE-A3 + AS15 CANCER IMMUNOTHERAPEUTIC AS ADJUVANT THERAPY IN PATIENTS WITH RESECTED MAGE-A3-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC).

N. Altorki, P. Therasse, T. Mitsudomi, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Selection of immunostimulant AS15 for active immunization with MAGE-A3 protein: results of a randomized phase II study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma.

A. Eggermont, A. Testori, J. Grob, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Th1/IFNg Gene Signature Is Prognostic in the Adjuvant Setting of Resectable High-Risk Melanoma but Not in Non–Small Cell Lung Cancer

J. Goeman, H. V. Houwelingen, J. Kirkwood, 2020 .

An HLA-A 2-restr icted Tyrosinase Ant igen on Melanoma Cells Results f rom Posttranslational Modif ication and Suggests a Novel Pathway for Processing o f Membrane Proteins

J. Shabanowitz, C. Slingluff, V. Brichard, 2003 .

Identification of genes coding for tumor antigens recognized by cytolytic T lymphocytes.

J. Renauld, P. Coulie, P. Bruggen, 1997, Methods.

Genes Coding for Tumor Antigens Recognized by Cytolytic T Lymphocytes

J. Renauld, C. Uyttenhove, P. Coulie, 1995, Immunological reviews.

New tumor antigens recognized by T cells.

B. J. Van den Eynde, V. Brichard, B. D. V. Eynde, 1995, Current opinion in immunology.

Analysis of antigens recognized on human melanoma cells by A2‐restricted cytolytic t lymphocytes (CTL)

T. Boon, M. Hauer, T. Wölfel, 1993, International journal of cancer.

A tyrosinase peptide presented by HLA‐B35 is recognized on a human melanoma by autologous cytotoxic T lymphocytes

T. Wölfel, P. van der Bruggen, B. J. Van den Eynde, 1999, International journal of cancer.

An HLA-A2 restricted tyrosinase epitope on melanoma cells results from post-translational modification

J. Shabanowitz, D. Hunt, V. Engelhard, 1995 .

An HLA-A2-restricted tyrosinase antigen on melanoma cells results from posttranslational modification and suggests a novel pathway for processing of membrane proteins

J. Shabanowitz, D. Hunt, V. Engelhard, 1996, The Journal of experimental medicine.

GSK's antigen-specific cancer immunotherapy programme: pilot results leading to Phase III clinical development.

D. Lejeune, V. Brichard, 2007, Vaccine.

Cancer immunotherapy targeting tumour-specific antigens: towards a new therapy for minimal residual disease.

D. Lejeune, V. Brichard, 2008, Expert opinion on biological therapy.

Diet‐ and diabetes‐induced changes of ob gene expression in rat adipose tissue

S. Brichard, J. Henquin, V. Brichard, 1995, FEBS letters.

Cytolytic T lymphocyte recognition of the immunodominant HLA-A*0201-restricted Melan-A/MART-1 antigenic peptide in melanoma.

P. Romero, D. Valmori, F. Jotereau, 1997, Journal of immunology.

Individual differences in the orientation of the cytolytic T cell response against mouse tumor P815

T. Boon, S. Lucas, A. van Pel, 1995, European journal of immunology.

Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE‐3 and presented by HLA‐A1

P. Coulie, Y. Humblet, B. Dréno, 1999, International journal of cancer.

Cancer regression and neurological toxicity cases after anti-MAGE-A3 TCR gene therapy.

J. Louahed, V. Brichard, T. Clay, 2013, Journal of immunotherapy.

A Th1/IFN g Gene Signature Is Prognostic in the Adjuvant Setting of Resectable High-Risk Melanoma but Not in Non – Small Cell Lung Cancer A

J. Goeman, H. V. Houwelingen, J. Kirkwood, 2020 .

A non-randomized dose-escalation Phase I trial of a protein-based immunotherapeutic for the treatment of breast cancer patients with HER2-overexpressing tumors

A. Callegaro, G. Curigliano, M. Campone, 2016, Breast Cancer Research and Treatment.

Adjuvant MAGE-A3 immunotherapy in resected non-small-cell lung cancer: phase II randomized study results.

T. Treasure, J. Jassem, J. Vansteenkiste, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

MAGE-A3-specific anticancer immunotherapy in the clinical practice

V. Brichard, Q. Godechal, 2013, Oncoimmunology.

MAGE-A3 cancer immunotherapeutic in resected stage IB-III NSCLC patients with or without sequential or concurrent chemotherapy.

G. Fasola, D. Atanackovic, J. Vansteenkiste, 2012 .

IFN-gamma responses in peptide-treated melanoma patients measured by an ELISPOT assay using allogeneic dendritic cells.

S. Gabrielsson, C. Bonnerot, T. Dorval, 2004, Anticancer research.

Overlapping peptides of melanocyte differentiation antigen melan‐A/MART‐1 recognized by autologous cytolytic T lymphocytes in association with HLA‐B45.1 and HLA‐A2.1

T. Boon, K. Meyer zum Büschenfelde, T. Wölfel, 1998, International journal of cancer.

Phase I dose-escalation trial of a recombinant HER2 vaccine in patients with Stage II/III HER2+ breast cancer

M. Piccart, G. Curigliano, M. Campone, 2005 .

Immunization With a Recombinant MAGE-A3 Protein After High-dose Therapy for Myeloma

F. Zhan, B. Barlogie, J. Shaughnessy, 2007, Journal of immunotherapy.

Identification of a MAGE-1 peptide recognized by cytolytic T lymphocytes on HLA-B*5701 tumors.

T. Boon, P. van der Bruggen, V. Stroobant, 2004, Tissue antigens.

Immunization with recombinant MAGE-A3 protein combined with adjuvant systems AS15 or AS02B in patients with unresectable and progressive metastatic cutaneous melanoma: A randomized open-label phase II study of the EORTC Melanoma Group (16032- 18031)

V. Chiarion-Sileni, M. Maio, B. Dréno, 2008 .

Cytotoxic T-lymphoc ' te clones from different patients display limited T-cell-receptor variable-region gene usage in HLA-A 2-restricted recognition of the melanoma antigen MelanA / MART-1

C. Farina, G. Nicolini, A. Anichini, 2005 .

Tumor antigens recognized by cytolytic T lymphocytes

P. Coulie, P. Bruggen, T. Boon, 1995 .

New data on MAGE-A3 cancer immunotherapy may signal new options for patients with melanoma and non-small cell lung cancer

D. Lejeune, V. Brichard, 2010 .

Human tumour antigens recognized by T-cells: perspectives for new cancer vaccines.

P. Coulie, T. Boon, P. van der Bruggen, 1995, Biochemical Society transactions.

Tumoral and immunologic response after vaccination of melanoma patients with an ALVAC virus encoding MAGE antigens recognized by T cells.

D. Speiser, P. Coulie, J. Tartaglia, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Dermatomyositis occurring during treatment of a patient with metastatic melanoma.

O. Dereure, J. Baurain, B. Guillot, 2004, Melanoma research.

The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas

P. Coulie, T. Boon, T. Wölfel, 1993, The Journal of experimental medicine.

Safety and immunogenicity of the PRAME cancer immunotherapeutic in metastatic melanoma: results of a phase I dose escalation study

J. Utikal, A. Hauschild, D. Schadendorf, 2016, ESMO Open.

A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas

J. Renauld, P. Coulie, T. Boon, 1994, The Journal of experimental medicine.

A peptide recognized by human cytolytic T lymphocytes on HLA-A2 melanomas is encoded by an intron sequence of the N- acetylglucosaminyltransferase V gene

F. Brasseur, C. Viret, T. Boon, 1996, The Journal of experimental medicine.

A phase I/II trial of the safety and clinical activity of a HER2-protein based immunotherapeutic for treating women with HER2-positive metastatic breast cancer

A. Callegaro, G. Curigliano, M. Campone, 2016, Breast Cancer Research and Treatment.

Toll-like receptor 4 stimulation with the detoxified ligand monophosphoryl lipid A improves Alzheimer’s disease-related pathology

Jean-Philippe Michaud, S. Rivest, C. Cluff, 2013, Proceedings of the National Academy of Sciences.

Prospective assessment of a gene signature potentially predictive of clinical benefit in metastatic melanoma patients following MAGE-A3 immunotherapeutic (PREDICT)

A. Enk, A. Hauschild, P. Murawa, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial.

Moon Soo Kim, N. Altorki, P. Therasse, 2016, The Lancet. Oncology.

Association of gene expression signature and clinical efficacy of MAGE-A3 antigen-specific cancer immunotherapeutic (ASCI) as adjuvant therapy in resected stage IB/II non-small cell lung cancer (NSCLC)

Jamila Louahed, Marcin Zieliński, Vincent Brichard, 2008 .

Two tyrosinase nonapeptides recognized on HLA‐A2 melanomas by autologous cytolytic T lymphocytes

B. Seliger, T. Boon, T. Wölfel, 1994, European journal of immunology.

Final results of a multi-center, double-blind, randomized, placebo-controlled phase II study to assess the efficacy of MAGE-A3 immunotherapeutic as adjuvant therapy in stage IB/II non-small cell lung cancer (NSCLC)

J. Jassem, E. Esteban, J. Vansteenkiste, 2007 .

A tyrosinase nonapeptide presented by HLA‐B44 is recognized on a human melanoma by autologous cytolytic T lymphocytes

T. Boon, T. Wölfel, A. van Pel, 1996, European journal of immunology.

Clinical response to the MAGE-A3 immunotherapeutic in metastatic melanoma patients is associated with a specific gene profile present prior to treatment

P. Dupont, B. Dréno, F. Lehmann, 2008 .

Cancer immunotherapy targeting tumour-specific antigens: towards a new therapy for minimal residual disease

D. Lejeune, V. Brichard, 2008, Expert opinion on biological therapy.

MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial.

A. Hauschild, S. Puig, J. Goeman, 2018, The Lancet. Oncology.

A monoclonal cytolytic T-lymphocyte response observed in a melanoma patient vaccinated with a tumor-specific antigenic peptide encoded by gene MAGE-3

P. Coulie, T. Boon, V. Karanikas, 2001, Proceedings of the National Academy of Sciences of the United States of America.

Gene Signature in Melanoma Associated With Clinical Activity: A Potential Clue to Unlock Cancer Immunotherapy

T. Gajewski, J. Louahed, V. Brichard, 2010, Cancer journal.

Expression of defined genes identified by pretreatment tumor profiling: Association with clinical responses to the GSK MAGE- A3 immunotherapeutic in metastatic melanoma patients (EORTC 16032–18031)

A. Eggermont, B. Dréno, F. Lehmann, 2008 .

A Th1/IFNγ Gene Signature Is Prognostic in the Adjuvant Setting of Resectable High-Risk Melanoma but Not in Non–Small Cell Lung Cancer

J. Goeman, H. V. van Houwelingen, J. Kirkwood, 2019, Clinical Cancer Research.

TRIAL A phase I / II trial of the safety and clinical activity of a HER 2-protein based immunotherapeutic for treating women with HER 2-positive metastatic breast cancer

A. Callegaro, G. Curigliano, M. Campone, 2016 .

Recurrent T cell receptor rearrangements in the cytotoxic T lymphocyte response in vivo against the p815 murine tumor

P. Kourilsky, J. Levraud, C. Pannetier, 1996, The Journal of experimental medicine.

Breast cancer vaccines: a clinical reality or fairy tale?

A. Goldhirsch, F. D. De Braud, G. Curigliano, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Recombinant protein vaccination for antigen-specific cancer immunotherapy

V. Brichard, P. Alves, 2011 .

Genes coding for tumor rejection antigens: perspectives for specific immunotherapy.

P. Coulie, T. Boon, T. Wölfel, 1994, Important advances in oncology.

Genes Coding for Tumor Rejection Antigens

Benoît Van den Eynde, Pierre van der Bruggen, Thierry Boon, 1992 .

Structure of the gene of tum‐ transplantation antigen P35B: presence of a point mutation in the antigenic allele.

T. Boon, N. van Baren, A. van Pel, 1990, The EMBO journal.

Multi-center, double-blind, randomized, placebo-controlled phase II study to assess the efficacy of recombinant MAGE-A3 vaccine as adjuvant therapy in stage IB/II MAGE-A3-positive, completely resected, non-small cell lung cancer (NSCLC).

J. Jassem, J. Vansteenkiste, B. Passlick, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A randomized phase I/II trial of antitumor vaccination using the recombinant MAGE-A3 protein loaded on myeloid DC or mixed with adjuvant ASO2B in melanoma patients

M. Toungouz, M. Goldman, T. Velu, 2005 .

Endometrial evaluation is a very important tool in the management of breast cancer patients.

M. Berlière, C. Galant, J. Donnez, 2002, European journal of cancer.

The prevalence of expression of MAGE-A3 and PRAME tumor antigens in East and South East Asian non-small cell lung cancer patients.

S. Thongprasert, Pan‐Chyr Yang, R. Soo, 2016, Lung cancer.

Phase 1/2 study of subcutaneous and intradermal immunization with a recombinant MAGE‐3 protein in patients with detectable metastatic melanoma

A. Eggermont, B. Dréno, F. Brasseur, 2005, International journal of cancer.

1105PVEMURAFENIB FOR BRAF V600 MUTATED ADVANCED MELANOMA: RESULTS OF TREATMENT BEYOND PROGRESSION.

Y. S. Kim, Su Jin Lee, J. Utikal, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Abstract A37: Identification of a gene expression signature predictive of clinical activity following MAGE‐A3 ASCI treatment

J. Vansteenkiste, B. Dizier, Fernando Ulloa-Montoya, 2009 .

118 POSTER Comprehensive preclinical model evaluating a protein-based MAGE-A3 specific cancer immunotherapy to fight against MAGE-A3 expressing tumors

C. Gerard, V. Brichard, N. Baudson, 2006 .

Breast cancer vaccines: a clinical reality or fairy tale?

A. Goldhirsch, G. Curigliano, G. Bonizzi, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Non-small cell lung cancer, early stage

L. Bubendorf, T. Yamanaka, M. Okada, 2012 .

Active immunization toward the MAGE-A3 antigen in patients with metastatic melanoma: Four-year follow-up results from a randomized phase II study (EORTC16032-18031).

A. Eggermont, V. Chiarion-Sileni, B. Dréno, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

MAGRIT phase III trial: MAGE-A3 antigen-specific cancer immunotherapy (ASCI) as adjuvant therapy in patients with completely resected stage IB-IIIA NSCLC.

L. Sequist, P. Therasse, T. Mok, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.